Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
45th European Brain and Behaviour Society Meeting
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
β-Amyloid: Enemy or Remedy?
Gene Expression & Signaling in the Immune System
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
A gender gap in autoimmunity.
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Studying both sexes: a guiding principle for biomedicine.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Gordon Research Conference on Ion Channels
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Power estimation for non-standardized multisite studies.

Pages